

DAFTAR PUSTAKA

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA: a cancer journal for clinicians*. 2019;69(1):7-34.
2. Seigel R. American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. 2020.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 2018;68(6):394-424.
4. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. *Nat Rev Dis Primers*. 2015;1:15065.
5. Lotfollahzadeh S, Recio-Boiles A, Cagir B. Colon Cancer. *StatPearls [Internet]* StatPearls Publishing. 2022.
6. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? *Clinical chemistry*. 2001;47(4):624-30.
7. Song Y, Huang Z, Kang Y, Lin Z, Lu P, Lin Q, et al. Clinical usefulness and prognostic value of red cell distribution width in colorectal cancer. *BioMed Research International*. 2018;2018.
8. Shi C, Xie M, Li L, Li K, Hu B-L. The association and diagnostic value of red blood cell distribution width in colorectal cancer. *Medicine*. 2019;98(19).
9. WHO. CANCER 2020 [Available from: <https://www.who.int/health-topics/cancer>].
10. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. *International journal of molecular sciences*. 2017;18(1):197.
11. International WCRF. Colorectal Cancer Statistics 2020 [Available from: <https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/>].

12. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. *Gastroenterology Review/Przegląd Gastroenterologiczny*. 2019;14(2):89-103.
13. Kimman M, Norman R, Jan S, Kingston D, Woodward M. The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). *Asian Pacific journal of cancer prevention*. 2012;13(2):411-20.
14. Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. *The lancet Gastroenterology & hepatology*. 2019;4(7):511-8.
15. Deng Y. Rectal cancer in Asian vs. Western countries: why the variation in incidence? *Current treatment options in oncology*. 2017;18(10):1-8.
16. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. *Cancers*. 2021;13(9):2025.
17. Kolligs FT. Diagnostics and epidemiology of colorectal cancer. *Visceral medicine*. 2016;32(3):158-64.
18. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut*. 2017;66(4):683-91.
19. Khalili H, Wolpin BM, Huang ES, Giovannucci EL, Kraft P, Fuchs CS, et al. ABO Blood Group and Risk of Colorectal Cancer ABO Blood Group and Colorectal Cancer. *Cancer epidemiology, biomarkers & prevention*. 2011;20(5):1017-20.
20. Al-Sawat A, Alswat S, Alosaimi R, Alharthi M, Alsuwat M, Alhasani K, et al. Relationship Between ABO Blood Group and the Risk of Colorectal Cancer: A Retrospective Multicenter Study. *Journal of Clinical Medicine Research*. 2022;14(3):119.

21. Huang JY, Wang R, Gao Y-T, Yuan J-M. ABO blood type and the risk of cancer—Findings from the Shanghai Cohort Study. *PloS one*. 2017;12(9):e0184295.
22. Thanikachalam K, Khan G. Colorectal cancer and nutrition. *Nutrients*. 2019;11(1):164.
23. Shivappa N, Godos J, Hébert JR, Wirth MD, Piuri G, Speciani AF, et al. Dietary inflammatory index and colorectal cancer risk—a meta-analysis. *Nutrients*. 2017;9(9):1043.
24. Świdarska M, Choromańska B, Dąbrowska E, Konarzewska-Duchnowska E, Choromańska K, Szczurko G, et al. The diagnostics of colorectal cancer. *Contemporary Oncology/Współczesna Onkologia*. 2014;18(1):1-6.
25. Boyle P, Leon ME. Epidemiology of colorectal cancer. *British medical bulletin*. 2002;64(1):1-25.
26. Liang PS, Chen TY, Giovannucci E. Cigarette smoking and colorectal cancer incidence and mortality: Systematic review and meta-analysis. *International journal of cancer*. 2009;124(10):2406-15.
27. Lewandowska A, Rudzki G, Lewandowski T, Strykowska-Góra A, Rudzki S. Risk factors for the diagnosis of colorectal cancer. *Cancer Control*. 2022;29:10732748211056692.
28. Klarich DS, Brasser SM, Hong MY. Moderate alcohol consumption and colorectal cancer risk. *Alcoholism: Clinical and Experimental Research*. 2015;39(8):1280-91.
29. Simon K. Colorectal cancer development and advances in screening. *Clinical interventions in aging*. 2016;11:967.
30. Brunicardi FC. Colon, Rectum and Anus. In: Mary R. Kwaan DBSS, Kelli Bullard Dunn, editor. *Schwartz's Principles of Surgery*. 11th ed. Toronto: Mc Graw Hill Education; 2019. p. 1288-93.
31. Vinay Kumar AKA, Jon C Aster. Small and Large Intestines. In: Vinay Kumar AKA, Jon C Aster, editor. *Robbins Basic Pathology*. Tenth ed. Philadelphia: Elsevier; 2018. p. 627-34.

32. Hermanek P. Colorectal carcinoma: histopathological diagnosis and staging. *Baillière's clinical gastroenterology*. 1989;3(3):511-29.
33. Baniyas L, Jung I, Chiciudean R, Gurzu S. From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer. *International Journal of Molecular Sciences*. 2022;23(16):9455.
34. Institute NC. Colon Cancer Treatment (PDQ®)–Patient Version 2022 [updated April 6th 2022. Available from: <https://www.cancer.gov/types/colorectal/patient/colon-treatment-pdq>.
35. Nasional KPK. Panduan Penatalaksanaan Kanker Kolorektal. In: Indonesia KKR, editor.: Kementrian Kesehatan Republik Indonesia; 2017.
36. Benson AB, Venook AP, Cederquist L, Chan E, Chen Y-J, Cooper HS, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*. 2017;15(3):370-98.
37. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. *Cancer investigation*. 2005;23(4):338-51.
38. Vauthey JN, Dudrick PS, Lind S, Copeland III EM. Management of recurrent colorectal cancer: another look at carcinoembryonic antigen-detected recurrence. *Digestive Diseases*. 1996;14(1):5-13.
39. Hammarström S, editor The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. *Seminars in cancer biology*; 1999: Elsevier.
40. Hao C, Zhang G, Zhang L. Serum CEA levels in 49 different types of cancer and noncancer diseases. *Progress in molecular biology and translational science*. 2019;162:213-27.
41. Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients-is it important? *Clinics*. 2009;64:287-94.

42. Huh JW, Kim CH, Lim SW, Kim HR, Kim YJ. Factors predicting long-term survival in colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. *Journal of cancer research and clinical oncology*. 2013;139(9):1449-55.
43. Huh JW, Oh BR, Kim HR, Kim YJ. Preoperative carcinoembryonic antigen level as an independent prognostic factor in potentially curative colon cancer. *Journal of surgical oncology*. 2010;101(5):396-400.
44. Huang S-H, Tsai W-S, You J-F, Hung H-Y, Yeh C-Y, Hsieh P-S, et al. Preoperative carcinoembryonic antigen as a poor prognostic factor in stage I–III colorectal cancer after curative-intent resection: a propensity score matching analysis. *Annals of surgical oncology*. 2019;26(6):1685-94.
45. Tarantino I, Warschkow R, Worni M, Merati-Kashani K, Köberle D, Schmied B, et al. Elevated preoperative CEA is associated with worse survival in stage I–III rectal cancer patients. *British journal of cancer*. 2012;107(2):266-74.
46. Ramphal W, Boeding JR, van Iwaarden M, Schreinemakers JM, Rutten HJ, Crolla RM, et al. Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer. *The International journal of biological markers*. 2019;34(1):60-8.
47. Beom S-H, Shin SJ, Kim CG, Kim JH, Hur H, Min BS, et al. Clinical significance of preoperative serum carcinoembryonic antigen within the normal range in colorectal cancer patients undergoing curative resection. *Annals of surgical oncology*. 2020;27(8):2774-83.
48. Yeh C-Y, Hsieh P-S, Chiang J-M, Lai C-C, Chen J-S, Wang J-Y, et al. Preoperative carcinoembryonic antigen elevation in colorectal cancer. *Hepato-gastroenterology*. 2011;58(109):1171-6.
49. Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. *Annals of surgical oncology*. 2008;15(12):3433-9.

50. Hall JE. Guyton and Hall : Textbook of Medical Physiology. 12th ed. Philadelphia: Saunders Elsevier; 2011.
51. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. *Critical reviews in clinical laboratory sciences*. 2015;52(2):86-105.
52. May JE, Marques MB, Reddy VV, Gangaraju R. Three neglected numbers in the CBC: The RDW, MPV, and NRBC count. *Cleve Clin J Med*. 2019;86(3):167-72.
53. Evans TC, Jehle D. The red blood cell distribution width. *The Journal of emergency medicine*. 1991;9:71-4.
54. Yang D, Quan W, Wu J, Ji X, Dai Y, Xiao W, et al. The value of red blood cell distribution width in diagnosis of patients with colorectal cancer. *Clinica chimica acta*. 2018;479:98-102.
55. Fancellu A, Zinellu A, Mangoni AA, Popova A, Galotti F, Feo CF, et al. Red Blood Cell Distribution Width (RDW) Correlates to the Anatomical Location of Colorectal Cancer. Implications for Clinical Use. *Journal of gastrointestinal cancer*. 2021:1-6.
56. Spell DW, Jones Jr DV, Harper WF, Bessman JD. The value of a complete blood count in predicting cancer of the colon. *Cancer detection and prevention*. 2004;28(1):37-42.
57. Cheng K-C, Lin Y-M, Liu C-C, Wu K-L, Lee K-C. High red cell distribution width is associated with worse prognosis in early colorectal cancer after curative resection: a propensity-matched analysis. *Cancers*. 2022;14(4):945.
58. Li Y, Xing C, Wei M, Wu H, Hu X, Li S, et al. Combining red blood cell distribution width (RDW-CV) and CEA predict poor prognosis for survival outcomes in colorectal cancer. *Journal of Cancer*. 2019;10(5):1162.

Lampiran 1 : Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari., MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 555A/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 9 Agustus 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23070454	No Sponsor	
Peneliti Utama	dr. Nur Ramadhiany Lihawa	Sponsor	
Judul Peneliti	Korelasi Red Blood Cell Distribution Width – Coefficient Variation (RDW-CV) dan Carcinoembryonic Antigen (CEA) terhadap Klinikopatologis Pasien Kanker Kolorektal di Makassar		
No Versi Protokol	1	Tanggal Versi	3 Juli 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 9 Agustus 2023 sampai 9 Agustus 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2 : Biodata Penulis

DAFTAR RIWAYAT HIDUP

Data Pribadi

Nama : Nur Ramadhiany Lihawa
Tempat, tanggal lahir : Gorontalo, 9 April 1989
Jenis kelamin : Perempuan
Status Perkawinan : Cerai hidup
Kewarganegaraan : Indonesia
Agama : Islam
Alamat : Jl. Nani Wartabone, RT 001/ RW 001,
Kel. Padebuolo, Kec. Kota Timur, Kota
Gorontalo
Telepon : 085298801919
e-mail : nurramadhianylihawa@gmail.com

Riwayat Pendidikan

- Riwayat Pendidikan Formal
 - 1996 – 1998 : SDN Sudirman I Makassar
 - 1998 – 2001 : SD Katolik Renya Rosari, Makale, Tana Toraja
 - 2001 – 2004 : SMP Negeri 1 Makale, Tana Toraja
 - 2004 – 2007 : SMA Negeri 17 Makassar
 - 2007 – 2010 : Fakultas Kedokteran, Universitas Hasanuddin
 - 2010 – 2013 : Profesi Dokter Fakultas Kedokteran, Universitas Hasanuddin
- Riwayat Pendidikan Non Formal
 - 2014 : Pelatihan Advance Trauma Life Support (ATLS) di Makassar
 - 2014 : Pelatihan EKG Dasar di Makassar
 - 2015 : Pelatihan Advance Cardiac Life Support (ACLS) di PERKI Makassar
 - 2019 : Pelatihan Basic Skill Surgery (BSS) Course for GP di Surabaya

Riwayat Pekerjaan

- Dokter Umum (Kontrak) RSUD Toto Kabila Kabupaten Bone Bolango, Kota Gorontalo, Maret 2015 – Maret 2019
- Dokter Umum (CPNS) RSUD Toto Kabila Kabupaten Bone Bolango, Kota Gorontalo, Maret 2019
- Dokter Umum RS Multazam Kota Gorontalo, Maret 2018 – Juni 2019
- Dokter Umum RS Islam Kota Gorontalo, Oktober 2018 – Juni 2019